A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > ORGANIZATION
ORGANIZATION
- Participation in TPP to Lead to Higher NHI Prices: JMA VP Nakagawa
May 10, 2012
- 87% of Respondents Affirmative on Introduction of Medicoeconomic Assessment: JAPhMed Survey
May 9, 2012
- JPMA Compiles Manual for Providing Drugs in the Event of Disasters
April 24, 2012
- JPMA Opposes Haste Adoption of Cost-Effective HTA
April 20, 2012
- National Centers for Advanced and Specialized Medical Cares to Join NHO, JLHWO Hospitals in Joint Purchasing
April 20, 2012
- Degree of Drug Contribution Increased Most for HIV and AIDS: JHSF Survey
April 13, 2012
- MREAC Seeks to Contact 70 People Who Passed MR Exam through “Transitional Measure”
April 10, 2012
- CMRs Exceed 3000, Rapidly Increasing in Specialty Care: JCSOA
April 6, 2012
- 4 Specific Measures for Distribution Improvement: JPWA President Bessho
March 29, 2012
- JGA Announces GL for Disclosure of Payments to Medical Institutions by Member Companies
March 29, 2012
- JGA Announces Measures to Ensure Stable Supplies of Generic Drugs
March 27, 2012
- JGA to Start Providing Information in July on Out of Stock Generics
March 27, 2012
- NIBIO Offers Clinical Trial Information on Rare Diseases on Website
March 26, 2012
- Growth of Domestic Pharma Industry Will Require Individualized Strategies: FPMAJ Chairman Shoda
March 23, 2012
- IDMA President Doshi Expresses Hopes for Cooperation with Japanese Pharmaceutical Companies
March 21, 2012
- Drugstore Market Reaches ¥5.8 Trillion, 11 Straight Years of Growth: JACDS Survey
March 19, 2012
- Asia Partnership Conference Starts Talks for Early NDA Approval at Inauguration Meeting in Tokyo
March 19, 2012
- JMA “Totally Opposed” to Japan’s Participation in TPP
March 16, 2012
- JPMA Compiles Policies for Transparency in Patient Group Relationships, Disclosure for States of Donations
March 15, 2012
- Wholesale Industry FTC to “Watch Closely” How Drug Makers Respond to Tougher Rules on Business Entertaining
March 7, 2012
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…